Who Buys Lenalidomide from India — 557 Importers Behind a $883.1M Market
India's lenalidomide import market is served by 557 active buyers who collectively imported $883.1M across 2,724 shipments. SUN PHARMACEUTICAL INDUSTRIES,INC. (UNITED STATES) leads with a 21.6% market share, followed by SUN PHARMACEUTICAL INDUSTRIESINC. and AUROBINDO PHARMA USA., INC,. The top 5 buyers together control 69.1% of total import value, reflecting a concentrated buyer landscape.
Top Lenalidomide Importers — Ranked by Import Value
SUN PHARMACEUTICAL INDUSTRIES,INC. (UNITED STATES) is the leading lenalidomide importer from India, holding a 21.6% share of the $883.1M market across 2,724 shipments from 557 buyers. The top 5 buyers — SUN PHARMACEUTICAL INDUSTRIES,INC. (UNITED STATES), SUN PHARMACEUTICAL INDUSTRIESINC. (UNITED STATES), AUROBINDO PHARMA USA., INC, (UNITED STATES), SUN PHARMACEUTICAL INDUSTRIES INC (UNITED STATES), CIPLA USA INC UPS SUPPLY CHAIN SOL (UNITED STATES) — collectively control 69.1% of total import value.
Top Lenalidomide Buyers & Importers
Ranked by import value · 557 active buyers · Indian Customs (DGFT) data
| # | Buyer & Formulations | Value | Suppliers | Share |
|---|---|---|---|---|
| 1 | SUN PHARMACEUTICAL INDUSTRIES,INC.UNITED STATES LENALIDOMIDE CAPS 25MG US 21S BOTTLELENALIDOMIDE CAPSULES 10 MG 28C USALENALIDOMIDE CAPSULES 10MG [3960 PACK X28 CAPSULES] | $190.9M | 5 | 21.6% |
| 2 | SUN PHARMACEUTICAL INDUSTRIESINC.UNITED STATES LENALIDOMIDE CAPS 25MG US 21S BOTTLELENALIDOMIDE CAPSULES 10 MG 28C USALENALIDOMIDE CAPSULES 10MG [3960 PACK X28 CAPSULES] | $126.6M | 5 | 14.3% |
| 3 | AUROBINDO PHARMA USA., INC,UNITED STATES LENALIDOMIDE CAPS 25MG US 21S BOTTLELENALIDOMIDE CAPSULES 10 MG 28C USALENALIDOMIDE CAPSULES 10MG [3960 PACK X28 CAPSULES] | $114.8M | 5 | 13.0% |
| 4 | SUN PHARMACEUTICAL INDUSTRIES INCUNITED STATES LENALIDOMIDE CAPS 25MG US 21S BOTTLELENALIDOMIDE CAPSULES 10 MG 28C USALENALIDOMIDE CAPSULES 10MG [3960 PACK X28 CAPSULES] | $100.8M | 5 | 11.4% |
| 5 | CIPLA USA INC UPS SUPPLY CHAIN SOLUNITED STATES LENALIDOMIDE CAPS 25MG US 21S BOTTLELENALIDOMIDE CAPSULES 10 MG 28C USALENALIDOMIDE CAPSULES 10MG [3960 PACK X28 CAPSULES] | $77.0M | 5 | 8.7% |
| 6 | AUROBINDO PHARMA USA INCUNITED STATES LENALIDOMIDE CAPS 25MG US 21S BOTTLELENALIDOMIDE CAPSULES 10 MG 28C USALENALIDOMIDE CAPSULES 10MG [3960 PACK X28 CAPSULES] | $52.2M | 5 | 5.9% |
| 7 | SUN PHARMACEUTICAL INDUSTRIES,INC..UNITED STATES LENALIDOMIDE CAPS 25MG US 21S BOTTLELENALIDOMIDE CAPSULES 10 MG 28C USALENALIDOMIDE CAPSULES 10MG [3960 PACK X28 CAPSULES] | $49.4M | 5 | 5.6% |
| 8 | XXC (XXNG XXNG)XXO XXDJAPAN LENALIDOMIDE 5MG CAPSULESCIPLA LENALIDOMIDE 10MG CAPSULES (LENALILENALIDOMIDE 15MG CAPSULES | $5.5M | 5 | 0.6% |
| 9 | YUSEN LOGISTICS BENELUX BELGIUMBELGIUM LENALIDOMIDE CAPS 7.5MG 3X7'S GERMANY PALENALIDOMIDE CAPS 10MG 3X7'S GERMANY PACLENALIDOMIDE CAPSULES 5MG [8961 PACK X 3X7'S]NOS | $2.5M | 5 | 0.3% |
| 10 | BROCACEF NL HUBNETHERLANDS LENALIDOMIDE 15MG CAPSULESLENALIDOMIDE 10 MG CAPSULESLENALIDOMIDE 25MG CAPSULES | $2.0M | 5 | 0.2% |
| 11 | CIPLA COLOMBIA SAS Y O DEPOSITO UPSCOLOMBIA LENALIDOMIDE CAPS 25MG US 21S BOTTLELENALIDOMIDE CAPSULES 10 MG 28C USALENALIDOMIDE CAPSULES 10MG [3960 PACK X28 CAPSULES] | $1.3M | 5 | 0.1% |
| 12 | PHARMIS SARLMOROCCO LENALIDOMIDE 25 MG CAPSLENALIDOMIDE 25 MG CAPS1 PACK=3 STPLENALIDOMIDE 25MG CAPS :1 PACK =3 STP | $1.1M | 5 | 0.1% |
| 13 | BROCACEF HEALTHCARE LOGISTICS BVNETHERLANDS LENALIDOMIDE 15MG CAPSULESLENALIDOMIDE 10 MG CAPSULESLENALIDOMIDE 25MG CAPSULES | $1.1M | 5 | 0.1% |
| 14 | CIPLA AUSTRALIA PTY LTDAUSTRALIA LENALIDOMIDE CAPS 25MG US 21S BOTTLELENALIDOMIDE CAPSULES 10 MG 28C USALENALIDOMIDE CAPSULES 10MG [3960 PACK X28 CAPSULES] | $1.0M | 5 | 0.1% |
| 15 | TARO PHARMACEUTICALS INC.,CANADA TARO-LENALIDOMIDE CAPSULES 10MGTARO-LENALIDOMIDE CAP 10 MG 4X7'S CANADATARO-LENALIDOMIDE CAP20MG3X7S | $966.5K | 5 | 0.1% |
Related Analysis
Market Analysis: Top Importing Countries & Importers
Comprehensive geographic market intelligence dashboard
Which companies are buying Lenalidomide — and from which countries?
Flow of Lenalidomide exports from India: each country's share and the named importers behind the numbers
Lenalidomide — Buyer Countries to Key Importers
Trade flow: top importing countries → named buyer companies
Market Analysis: Top Importing Countries & Their Importers
1United States
United States emerges as the first largest importing country, achieving a total trade value of $853.7M through 79 shipments. This represents a market share of 96.7% of the total market activity, demonstrating their significant presence in the industry.
Top Importers: United States has a diverse importer base, with their top importers including:
• SUN PHARMACEUTICAL INDUSTRIES,INC. - $190.9M (22.4% of country's total business)
• SUN PHARMACEUTICAL INDUSTRIESINC. - $126.6M (14.8% of country's total business)
• AUROBINDO PHARMA USA., INC, - $114.8M (13.4% of country's total business)
• SUN PHARMACEUTICAL INDUSTRIES INC - $100.8M (11.8% of country's total business)
• CIPLA USA INC UPS SUPPLY CHAIN SOL - $77.0M (9.0% of country's total business)
• Rest of United States's importers - $243.5M (28.5% of country's total business)
Key Insight: United States demonstrates strong market positioning with an average shipment value of $10.8M, indicating premium pricing strategy compared to the market average of $324.2K.
United States is a key market for Lenalidomide imports, representing 96.7% of total trade value.
2Japan
Japan emerges as the second largest importing country, achieving a total trade value of $5.5M through 2 shipments. This represents a market share of 0.6% of the total market activity, demonstrating their significant presence in the industry.
Top Importers: Japan has a diverse importer base, with their top importers including:
• XXC (XXNG XXNG)XXO XXD - $5.5M (100.0% of country's total business)
Key Insight: Japan demonstrates strong market positioning with an average shipment value of $2.8M, indicating premium pricing strategy compared to the market average of $324.2K.
Japan is a key market for Lenalidomide imports, representing 0.6% of total trade value.
3Netherlands
Netherlands emerges as the third largest importing country, achieving a total trade value of $3.8M through 85 shipments. This represents a market share of 0.4% of the total market activity, demonstrating their significant presence in the industry.
Top Importers: Netherlands has a diverse importer base, with their top importers including:
• BROCACEF NL HUB - $2.0M (50.9% of country's total business)
• BROCACEF HEALTHCARE LOGISTICS BV - $1.1M (27.8% of country's total business)
Key Insight: Netherlands demonstrates strong market positioning with an average shipment value of $45.3K, indicating competitive pricing strategy compared to the market average of $324.2K.
Netherlands is a key market for Lenalidomide imports, representing 0.4% of total trade value.
4Canada
Canada emerges as the fourth largest importing country, achieving a total trade value of $3.8M through 8 shipments. This represents a market share of 0.4% of the total market activity, demonstrating their significant presence in the industry.
Top Importers: Canada has a diverse importer base, with their top importers including:
• TARO PHARMACEUTICALS INC., - $966.5K (25.6% of country's total business)
• TARO PHARMACEUTICALS INC - $966.0K (25.6% of country's total business)
• TARO PHARMACEUTICALS INC. - $949.1K (25.1% of country's total business)
Key Insight: Canada demonstrates strong market positioning with an average shipment value of $471.8K, indicating premium pricing strategy compared to the market average of $324.2K.
Canada is a key market for Lenalidomide imports, representing 0.4% of total trade value.
5Colombia
Colombia emerges as the fifth largest importing country, achieving a total trade value of $3.1M through 3 shipments. This represents a market share of 0.4% of the total market activity, demonstrating their significant presence in the industry.
Top Importers: Colombia has a diverse importer base, with their top importers including:
• CIPLA COLOMBIA SAS Y O DEPOSITO UPS - $1.3M (39.9% of country's total business)
Key Insight: Colombia demonstrates strong market positioning with an average shipment value of $1.0M, indicating premium pricing strategy compared to the market average of $324.2K.
Colombia is a key market for Lenalidomide imports, representing 0.4% of total trade value.
Buyer Segment Analysis
TransData Nexus Lenalidomide buyer market intelligence
1Buyer Segment Analysis
The 557 buyers of Lenalidomide from India can be categorized into several segments:
1. Pharmaceutical Companies: Entities like Sun Pharmaceutical Industries Inc. and Aurobindo Pharma USA Inc. are major buyers, accounting for significant import values. These companies typically procure large quantities to support their manufacturing and distribution operations, ensuring a steady supply chain for their products.
2. Distributors: Companies such as Yusen Logistics Benelux Belgium and Brocacef NL Hub in the Netherlands function as intermediaries, purchasing Lenalidomide in bulk and supplying it to various healthcare providers. Their buying behavior is characterized by regular, large-volume orders to meet the demands of their client base.
3. Re-exporters: Some buyers may act as re-exporters, importing Lenalidomide from India and then exporting it to other countries. This segment's order patterns are influenced by global market demands and regulatory environments in target markets.
Country-Specific Import Regulations
TransData Nexus Lenalidomide buyer market intelligence
1Country-Specific Import Regulations
For the top five importing countries, the import regulations for Lenalidomide are as follows:
1. United States:
2. Japan:
3. Netherlands:
4. Canada:
5. Colombia:
Demand Drivers & Market Opportunity
TransData Nexus Lenalidomide buyer market intelligence
1Demand Drivers & Market Opportunity
The demand for Lenalidomide in importing countries is driven by several factors:
1. Disease Prevalence: Lenalidomide is primarily used to treat multiple myeloma and certain types of anemia. The prevalence of these conditions influences demand. For instance, the American Cancer Society estimated that in 2025, approximately 35,000 new cases of multiple myeloma would be diagnosed in the United States, indicating a substantial patient population requiring treatment.
2. Government Healthcare Programs and Universal Health Coverage Expansion: Countries expanding their healthcare coverage increase access to essential medicines. For example, Canada's universal healthcare system ensures that approved medications like Lenalidomide are accessible to patients, thereby driving demand.
3. WHO Essential Medicines List Procurement and Tender-Based Purchasing: Lenalidomide's inclusion in the World Health Organization's List of Essential Medicines underscores its importance. Many countries rely on this list to guide procurement decisions, often through tender-based purchasing systems to ensure cost-effectiveness and supply security.
With 557 buyers across 122 countries, the global reach of Lenalidomide underscores its critical role in oncology treatment worldwide.
Common Questions — Lenalidomide Buyers & Importers
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
QWho is the largest lenalidomide buyer importing from India?
Based on import volume and value, SUN PHARMACEUTICAL INDUSTRIES,INC. (UNITED STATES) leads with $190.9M in imports and a 21.6% market share — the highest of any single lenalidomide importer. SUN PHARMACEUTICAL INDUSTRIESINC. (UNITED STATES) and AUROBINDO PHARMA USA., INC, (UNITED STATES) are the next largest buyers.
QHow many companies buy lenalidomide from India?
There are 557 active lenalidomide buyers importing from India, with a combined market of $883.1M across 2,724 shipments to 122 countries. The top 5 buyers hold 69.1% of total import value, while the remaining 552 buyers handle the other 30.9%.
QWhich countries import the most lenalidomide from India?
The top importing countries for lenalidomide from India are United States (96.7%), Japan (0.6%), Netherlands (0.4%), Canada (0.4%), Colombia (0.4%). These markets represent the largest demand centres for Indian pharmaceutical exports of lenalidomide, with buyers ranging from government procurement agencies to private pharmaceutical distributors.
QWhat is the average import order value for lenalidomide from India?
The average import transaction value for lenalidomide from India is $324.2K, with an average unit price of $134.82 per unit. Order sizes vary significantly based on buyer type — government tenders tend to be larger while private distributors place more frequent smaller orders.
Buyer Segment Analysis
TransData Nexus Lenalidomide buyer market intelligence
1Buyer Segment Analysis
The 557 buyers of Lenalidomide from India can be categorized into several segments:
1. Pharmaceutical Companies: Entities like Sun Pharmaceutical Industries Inc. and Aurobindo Pharma USA Inc. are major buyers, accounting for significant import values. These companies typically procure large quantities to support their manufacturing and distribution operations, ensuring a steady supply chain for their products.
2. Distributors: Companies such as Yusen Logistics Benelux Belgium and Brocacef NL Hub in the Netherlands function as intermediaries, purchasing Lenalidomide in bulk and supplying it to various healthcare providers. Their buying behavior is characterized by regular, large-volume orders to meet the demands of their client base.
3. Re-exporters: Some buyers may act as re-exporters, importing Lenalidomide from India and then exporting it to other countries. This segment's order patterns are influenced by global market demands and regulatory environments in target markets.
Country-Specific Import Regulations
TransData Nexus Lenalidomide buyer market intelligence
1Country-Specific Import Regulations
For the top five importing countries, the import regulations for Lenalidomide are as follows:
1. United States:
2. Japan:
3. Netherlands:
4. Canada:
5. Colombia:
Demand Drivers & Market Opportunity
TransData Nexus Lenalidomide buyer market intelligence
1Demand Drivers & Market Opportunity
The demand for Lenalidomide in importing countries is driven by several factors:
1. Disease Prevalence: Lenalidomide is primarily used to treat multiple myeloma and certain types of anemia. The prevalence of these conditions influences demand. For instance, the American Cancer Society estimated that in 2025, approximately 35,000 new cases of multiple myeloma would be diagnosed in the United States, indicating a substantial patient population requiring treatment.
2. Government Healthcare Programs and Universal Health Coverage Expansion: Countries expanding their healthcare coverage increase access to essential medicines. For example, Canada's universal healthcare system ensures that approved medications like Lenalidomide are accessible to patients, thereby driving demand.
3. WHO Essential Medicines List Procurement and Tender-Based Purchasing: Lenalidomide's inclusion in the World Health Organization's List of Essential Medicines underscores its importance. Many countries rely on this list to guide procurement decisions, often through tender-based purchasing systems to ensure cost-effectiveness and supply security.
With 557 buyers across 122 countries, the global reach of Lenalidomide underscores its critical role in oncology treatment worldwide.
Official References & Regulatory Resources
- European Medicines Agency
- WHO Essential Medicines
- Invest India — Pharma Sector
- India Trade Statistics (DGFT)
Verify import regulations and drug registration requirements with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Buyer Identification: 557 global importers of Lenalidomide identified from consignee fields in DGFT shipping bill records.
- 2.Import Value Analysis: Total import value aggregated from 2,724 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Geographic Distribution: Buyer imports distributed across 122 destination countries with market share per buyer calculated from capped values.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
2,724 Verified Shipments
557 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists